Inhibikase Therapeutics Files 2023 Annual Report on Form 10-K

TL;DR

<b>Inhibikase Therapeutics, Inc. has filed its 2023 Form 10-K detailing its financial position and operational events.</b>

AI Summary

Inhibikase Therapeutics, Inc. (IKT) filed a Annual Report (10-K) with the SEC on March 27, 2024. Inhibikase Therapeutics, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company's principal executive offices are located at 3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA 30339. The filing includes data related to common stock, warrants, and various financial measurements as of December 31, 2023. Key dates mentioned include January 25, 2023, for warrant-related events and February 1, 2024, for a subsequent event involving HC Wainwright & Co., LLC. The company operates in the Biological Products (No Diagnostic Substances) industry, SIC code 2836.

Why It Matters

For investors and stakeholders tracking Inhibikase Therapeutics, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of the company's financial health, operational activities, and strategic developments throughout 2023, which is crucial for investors to assess performance and future prospects. The detailed financial data, including information on common stock, warrants, and fair value measurements, allows stakeholders to understand the company's capital structure and asset valuation.

Risk Assessment

Risk Level: medium — Inhibikase Therapeutics, Inc. shows moderate risk based on this filing. The company is in the biotechnology sector, which is inherently high-risk due to long development cycles, regulatory hurdles, and clinical trial outcomes. The filing does not provide specific financial performance metrics or revenue figures, making it difficult to assess current operational success.

Analyst Insight

Investors should review the full 10-K to understand the company's financial condition, risk factors, and strategic priorities for the upcoming year.

Key Numbers

• 2023-12-31 — Fiscal Year End (The period covered by the 10-K filing.)
• 2024-03-27 — Filing Date (Date the 10-K was filed with the SEC.)
• 2836 — SIC Code (Standard Industrial Classification for Biological Products.)

Key Players & Entities

• Inhibikase Therapeutics, Inc. (company) — Filer of the 10-K report.
• HC Wainwright & Co., LLC (company) — Involved in a subsequent event on February 1, 2024.
• Atlanta, GA (location) — Location of the company's business and mailing address.

FAQ

Risk Factors

• Regulatory Risks [medium — regulatory]: The company is subject to extensive government regulation, including FDA requirements, which can impact product development and market approval.
• Need for Additional Financing [medium — financial]: The company may require significant additional capital to fund its ongoing operations and research and development activities.
• Dependence on Key Personnel [medium — operational]: The success of the company may depend on the continued service of its key scientific and management personnel.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
• 2024-03-27: 10-K Filing Date — Official date the annual report was submitted to the SEC.
• 2024-02-01: Subsequent Event — Involvement of HC Wainwright & Co., LLC.

Glossary

10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (Provides a detailed overview of the company's financial health and operations for the fiscal year.)

Warrant

A security that gives the holder the right, but not the obligation, to purchase shares of stock at a specific price before a certain expiration date. (Indicates potential future dilution and capital raising mechanisms for the company.)

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark
• $0.39 million — the National Institutes of Health, for $0.39 million to fund animal model studies of Risvode
• $12.2 billion — treatment costs are expected to exceed $12.2 billion. The country with the highest- diagnose

Filing Documents

• ikt-20231231.htm (10-K) — 2683KB
• ikt-ex14_1.htm (EX-14.1) — 90KB
• ikt-ex21_1.htm (EX-21.1) — 6KB
• ikt-ex23_1.htm (EX-23.1) — 10KB
• ikt-ex31_1.htm (EX-31.1) — 14KB
• ikt-ex31_2.htm (EX-31.2) — 14KB
• ikt-ex32_1.htm (EX-32.1) — 9KB
• ikt-ex32_2.htm (EX-32.2) — 9KB
• ikt-ex97_1.htm (EX-97.1) — 40KB
• img35665305_0.jpg (GRAPHIC) — 28KB
• img35665305_1.jpg (GRAPHIC) — 19KB
• 0000950170-24-037160.txt (&nbsp;) — 8759KB
• ikt-20231231.xsd (EX-101.SCH) — 1236KB
• ikt-20231231_htm.xml (XML) — 1087KB

Business

Business 2 Item 1A.

Risk Factors

Risk Factors 26 Item 1B. Unresolved Staff Comments 76 Item 1C. Cybersecurity 76 Item 2.

Properties

Properties 77 Item 3.

Legal Proceedings

Legal Proceedings 77 Item 4. Mine Safety Disclosures 77 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 78 Item 6. [Reserved] 78 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 79 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 88 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 88 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 88 Item 9A.

Controls and Procedures

Controls and Procedures 88 Item 9B. Other Information 88 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 88 PART III Item 10. Directors, Executive Officers and Corporate Governance 89 Item 11.

Executive Compensation

Executive Compensation 98 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 104 Item 13. Certain Relationships and Related Transactions, and Director Independence 105 Item 14. Principal Accounting Fees and Services 106 PART IV Item 15. Exhibits, Financial Statement Schedules F- 1 Item 16 Form 10-K Summary F- 3

Signatures

Signatures F- 4 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS All statements included or incorporated by reference in this Annual Report on Form 10-K, or the Report, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on our current expectations, estimates, approximations and projections about our industry and business, management's beliefs, and certain assumptions made by us, all of which are subject to change. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," and similar expressions and variations or negatives of these words. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, some of which are listed under "Risk Factors" in Item 1A of this Report. These forward-looking statements speak only as of the date of this Report. We undertake no obligation to revise or update publicly any forward-looking statement for any reason, except as otherwise required by law. In this Report, unless otherwise indicated, the "Company", "we," "us" or "our" refer to Inhibikase Therapeutics, Inc., a Delaware corporation and its subsidiary, IKT Securities Corporation, a Massachusetts corporation. The sources of industry and market data contained in this financial report primarily include those listed below: 1. S. Brahmachari, et al., "Activation of tyrosine kinase c-Abl contributes to -synuclein-induced neurodegeneration." J. Clin. Invest , 126: 2970-88 (2016). 2. X. Mao, et al., "Pathological -synuclein transmission initiated by binding lymphocyte-activa

Bu siness

Item 1. Bu siness. Company Overview We are a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The Company's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program utilizing Risvodetinib (also known as IkT-148009 ), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases. In 2021, we commenced clinical development of Risvodetinib (IkT-148009) , which we believe can modify the course of Parkinson's disease including its manifestation in the gastrointestinal tract, or GI. In January, 2023, the Company initiated its Phase 2 program, termed the 201 trial' (www.the201trial.com), for Risvodetinib (IkT-148009) as a treatment for Parkinson's disease and began the process of opening up to 34 sites in the U.S. As of March 22, 2024, 32 sites are open and actively evaluating prospective trial participants. 73 participants have been enrolled, 20 prospective participants are in medical screening and 48 potential participants are being evaluated for suitability to initiate medical screening. Thirty-four participants have completed the 12-week dosing period. As of March 22, 2024, 15 mild and two moderate possibly treatment-related adverse events have been reported across all enrolled patients taking Risvodetinib (IkT-148009). Depending on the timing of the last enrolled patient, results from this trial may be reported in the second-half of 2024. Monthly site enrollments have increased month-over-month since our patient outreach program was initiated. As such, we believe a more rapid path to enrollment is emerging through the public outreach/awareness campaign led by the the201trial.com' website. The emerging path to complete e

View Full Filing

View this 10-K filing on SEC EDGAR